Analysis of ABCG2 genotype in Gleevec treated cancer patients to assess the association of a single nucleotide polymorphism (C421A) in ABCG2 and response to treatment.

Trial Profile

Analysis of ABCG2 genotype in Gleevec treated cancer patients to assess the association of a single nucleotide polymorphism (C421A) in ABCG2 and response to treatment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2011

At a glance

  • Drugs Imatinib (Primary)
  • Indications Cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 24 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 May 2009 Additional lead trial investigator (Figg WD) identified as reported by ClinicalTrials.gov (NCT00897000)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top